

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8-3-05 Signature: Rhea Amid  
(Rhea Amid)



Patent  
Docket No. 532232000900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Adam SIDDIQUI-JAIN

Serial No.: 10/531,545

Filing Date: (Int'l) October 20, 2003

For: PROCESSES FOR IDENTIFYING  
QUADRUPLEX-TARGETED  
ANTIVIRAL MOLECULES

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 51, 60, and 93 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on June 22, 2004, directed to a counterpart international or foreign application and have not been previously cited.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - A fee is required. A check in the amount of \_\_ is enclosed.
  - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532232000900.

Dated: August 3, 2005

Respectfully submitted,

By   
Laurie L. Hill

Registration No.: 51,804  
MORRISON & FOERSTER LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
(858) 720-7955



Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/531,545
				Filing Date	(Int'l) October 20, 2003
				First Named Inventor	Adam SIDDIQUI-JAIN
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	532232000900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
1.	US-4,469,863	09-04-1984	Ts'o et al.		
2.	US-4,559,157	12-17-1985	Smith et al.		
3.	US-4,608,392	08-26-1986	Jacquet et al.		
4.	US-4,820,508	04-11-1989	Wortzman		
5.	US-4,938,949	07-03-1990	Borch et al.		
6.	US-4,992,478	02-12-1991	Geria		
7.	US-4,987,071	01-22-1991	Cech et al.		
8.	US-5,093,246	03-03-1992	Cech et al.		
9.	US-5,096,815	03-17-1992	Ladner et al.		
10.	US-5,116,742	05-26-1992	Cech et al.		
11.	US-5,198,346	03-30-1993	Ladner et al.		
12.	US-5,223,409	06-29-1993	Ladner et al.		
13.	US-5,403,484	04-04-1995	Ladner et al.		
14.	US-5,536,821	07-16-1996	Agrawal et al.		
15.	US-5,541,306	07-30-1996	Agrawal et al.		
16.	US-5,571,698	11-05-1996	Ladner et al.		
17.	US-5,614,622	03-25-1997	Radhakrishnan et al.		
18.	US-5,637,683	06-10-1997	Usher et al.		
19.	US-5,637,684	06-10-1997	Cook et al.		
20.	US-5,654,398	08-05-1997	Frankel et al.		
21.	US-5,700,922	12-23-1997	Cook et al.		
22.	US-5,703,055	12-30-1997	Felgner et al.		
23.	US-5,717,083	02-10-1998	Cook et al.		
24.	US-5,719,262	02-17-1998	Buchardt et al.		
25.	US-5,739,308	04-14-1998	Kandimalla et al.		
26.	US-5,739,314	04-14-1998	Roy et al.		
27.	US-5,759,768	06-02-1998	Haseltine et al.		
28.	US-5,766,905	06-16-1998	Studier et al.		
29.	US-5,773,601	06-30-1998	Agrawal		
30.	US-5,886,165	03-23-1999	Kandimalla et al.		
31.	US-5,900,481	05-04-1999	Lough et al.		
32.	US-5,929,226	07-27-1999	Padmapriya et al.		
33.	US-5,955,599	09-21-1999	Radhakrishnan et al.		
34.	US-5,962,674	10-05-1999	Iyer et al.		
35.	US-5,977,296	11-02-1999	Nielsen et al.		
36.	US-6,022,688	02-08-2000	Jurinke et al.		
37.	US-6,117,992	09-12-2000	Iyer		
38.	US-6,133,436	10-17-2000	Koster et al.		
39.	US-6,140,482	10-31-2000	Iyer et al.		
40.	US-6,214,560	04-10-2001	Yguerabide et al.		
41.	US-6,261,776	07-17-2001	Pirnung et al.		
42.	US-6,316,781	11-13-2001	Nagle et al.		

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					
(Use as many sheets as necessary)					
Sheet	2	of	3		
				Attorney Docket Number	532232000900

43.	US-6,379,974	04-30-2002	Parce et al.	
44.	US-6,429,025	08-06-2002	Parce et al.	
45.	US-6,440,722	08-27-2002	Knapp et al.	
46.	US-2004/0005601-A1	01-08-2004	Siddiqui-Jain et al.	

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	47.	WO-00/56746	09-28-2000	Kochkine et al.	
	48.	WO-00/75372	12-14-2000	Kim et al.	
	49.	WO-01/14398	03-01-2001	Garner	
	50.	WO-01/18234	03-15-2001	Austin et al.	
	51.	WO-02/072756	09-12-2002	Poeschla et al.	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	52.	ALTSCHUL et al., J. Mol. Biol. (1990) 215:403-410			
	53.	ALTSCHUL et al., Nucleic Acids Res. (1997) 25:3389-3402			
	54.	ANANTHA et al., Biochemistry (1998) 37:2709-2714			
	55.	ANSELL et al., Current Opin. in Biotechnology (1996) 7:89-94			
	56.	ARTHANARI and BOLTON, Anti-Cancer Drug Design (1999) 14:317-326			
	57.	BARTEL and SZOSTAK, Science (1993) 261:1411-1418			
	58.	CARELL et al., Angew. Chem. Int. Ed. Engl. (1994) 33:2061-2064			
	59.	CARELL et al., Angew. Chem. Int. Ed. Engl. (1994) 33:2059-2061			
	60.	CHARNEAU, J. of Virology (1992) 66:2814-2820			
	61.	CHO et al., Science (1993) 261:1303-1305			
	62.	Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989), pp. 6.3.1-6.3.6			
	63.	CWIRLA et al., PNAS USA (1990) 87:6378-6382			
	64.	DATTA et al., JACS (2001) 123:9612-9619			
	65.	DEVLIN, Science (1990) 249:404-406			
	66.	DE WITT et al., PNAS USA (1993) 90:6909-6913			
	67.	ELBASHIR et al., Methods (2002) 26:199-213			
	68.	ERB et al., PNAS USA (1994) 91:11422			
	69.	FELICI, J. Mol. Biol. (1991) 222:301-310			
	70.	FODOR, Nature (1993) 364:555-556			
	71.	GALLOP et al., J. Med. Chem. (1994) 37:1233-1251			
	72.	HAN et al., Nucl. Acids. Res. (1999) 27:537-542			

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/531,545
				Filing Date	(Int'l) October 20, 2003
				First Named Inventor	Adam SIDDIQUI-JAIN
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	532232000900

73.	HASELHOFF & GERLACH, <i>Nature</i> (1988) 334:585-591
74.	HE et al., <i>Science</i> (1998) 281:1509-1512
75.	HURLEY, <i>Nature Rev. Cancer</i> (2002) 2:188-200
76.	International Search Report for PCT/US03/33366, mailed on June 22, 2004, 1 page
77.	JIN and PIKE, <i>Mol. Endocrinol.</i> (1996) 10:196-205
78.	KIM et al., <i>J. Virol.</i> (1998) 72:811-816
79.	KRIZ et al., <i>Analytical Chemistry</i> (1995) 67:2142-2144
80.	LAM, <i>Nature</i> (1991) 354:82-84
81.	LYONNAIS et al., <i>Nucleic Acids Research</i> (2002) 30:5276-5283
82.	MEYERS & MILLER, <i>CABIOS</i> (1989) 4:11-17
83.	POSTEL et al., <i>Mol. Cell. Biol.</i> (1989) 9:5123-5133
84.	POSTEL, <i>J. Biol. Chem.</i> (1999) 274:22821-22829
85.	QU and CHAIRES, <i>Methods Enzymol.</i> (2000) 321:353-369
86.	REN et al., <i>Biochemistry</i> (1999) 38:16067-16075
87.	SCOTT and SMITH, <i>Science</i> (1990) 249:386-390
88.	SHEA, <i>Trends in Polymer Science</i> (1994) 2:166-173
89.	SIMONSSON and SJOBACK, <i>J. Biol. Chem.</i> (1999) 274:17379-17383
90.	SONEOKA et al., <i>Nucleic Acids Res.</i> (1995) 23:628-633
91.	VLATAKIS et al., <i>Nature</i> (1993) 361:645-647
92.	WEITZMANN et al., <i>J. Biol. Chem.</i> (1996) 271:20958-20964
93.	WHITWAM, <i>J. of Virology</i> (2001) 75:9407-9414
94.	ZUCKERMANN et al., <i>J. Med. Chem.</i> (1994) 37:2678-2685

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--